FGFR3 and non-small cell lung carcinoma: Further, FGFR3 (K650E), a product of an activating mutation, was identified in glioma, non-small-cell lung carcinoma (NSCLC), ES, and liposarcoma (LPS), and correlated with poor survival in patients with LPS (Helsten et al., 2016; Li et al., 2016; Lee et al., 2018).